News

Parkinson’s disease patients with inadequately controlled tremors are being sought for a Phase 2 clinical trial of suvecaltamide, an oral treatment candidate from Jazz Pharmaceuticals. The Phase 2 trial (NCT05642442), which enrolled its first participant late last year, seeks about 160 adults, ages 40-80, with Parkinson’s who have…

Parkinson’s UK is continuing to support work into a wearable device — called Cue Band — aiming to lessen chronic sialorrhea, the excessive drooling that often accompanies Parkinson’s disease. Having helped with Cue Band’s early development, the nonprofit is funding a planned test of the device’s at-home use in up to…

The U.S. Department of Defense has awarded $400,000 to an Augusta University (AU) neuroscientist to research a possible brain-gut connection in Parkinson’s disease. Danielle Mor, PhD, from the Medical College of Georgia at AU, will use the two-year Early-Investigator Research Award to explore whether Parkinson’s starts in the gut. Specifically,…

Inflammation in the brain is detectable at the earliest stages of Parkinson’s disease and even before treatment is begun, a new study reports. The findings support the idea that inflammation may be an early driver of Parkinson’s itself, rather than merely a byproduct of the disease’s neurodegeneration, the researchers…

Microglia, the brain’s resident immune cells, may contribute to Parkinson’s disease by releasing tiny vesicles filled with alpha-synuclein — the protein that builds up to toxic levels in Parkinson’s — a mouse study suggests. This release, which was associated with greater nerve cell damage and worse motor function, was…

The Black and African American Connections to Parkinson’s Disease (BLAAC PD) study, a research effort to understand the genetic complexities of Parkinson’s disease among traditionally underrepresented people, has now expanded to six clinical sites. A better understanding of genetic variants associated with the neurological condition specific to this…

A mutation in the SH3GL2 gene that’s associated with an increased risk of Parkinson’s disease contributes to a buildup of cellular debris in brain cells, a study discovered. According to researchers, that mutation was found to impair autophagy, an essential process by which cells recycle or breakdown components that…

Aptinyx’s investigational therapy NYX-458 failed to be superior to a placebo at improving cognitive function in people with dementia due to Parkinson’s disease or Lewy body dementia in a Phase 2 clinical trial. These findings prompted the company to stop development work on NYX-458. “We are very disappointed…

Jotrol, Jupiter Neuroscience’s oral formulation of resveratrol, significantly improved muscle strength, motor coordination, and behavior in a mouse model of Parkinson’s disease, the company reported. “This research demonstrates the neuroprotectant abilities of Jotrol as a potential treatment to prevent onset and progression of PD [Parkinson’s] symptoms,” said Alison…

People living in areas with high levels of an air pollutant called fine particulate matter (PM2.5) — whose sources include power plants, motorized vehicles, and fires — are at greater risk of Parkinson’s disease, according to a U.S. study. “We found a nationwide association between Parkinson’s disease and air pollution…